Data / Drug companies / Rising Pharma Holdings, Inc.
Rising Pharma Holdings, Inc.: 165 products in the FDA NDC directory, labeler code 57237
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Rising Pharma Holdings, Inc. (labeler code 57237) lists 165 products in the FDA National Drug Code Directory, covering 66 finished drugs by generic name. By type: 121 prescription drugs, 44 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 10, 2026.
The request: Watch Rising Pharma Holdings, Inc. (FDA labeler code 57237): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 57237
- Products in commercial distribution
- 165
- Packages
- 317
- Finished drugs by generic name
- 66
- Prescription products
- 121
- Over the counter products
- 44
- Controlled substance products
- Schedule IV 4
- Flagged as original packager
- 149 of 149 products that carry the flag
- Started marketing in the last 12 months
- 11
- Products with a marketing end date set
- 2
- Earliest marketing start
- October 22, 2004
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 127 | 77% |
| Over the counter monograph drugs | 35 | 21.2% |
| Other unapproved drugs | 3 | 1.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 121 | 73.3% |
| Over the counter drugs | 44 | 26.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 44 | 26.7% |
| Tablet, film coated | 40 | 24.2% |
| Capsule | 18 | 10.9% |
| Powder, for suspension | 8 | 4.8% |
| Solution | 8 | 4.8% |
| Tablet, orally disintegrating | 7 | 4.2% |
| Cream | 6 | 3.6% |
| Liquid | 5 | 3% |
| Suppository | 5 | 3% |
| Tablet, delayed release | 4 | 2.4% |
| Tablet, film coated, extended release | 4 | 2.4% |
| Capsule, delayed release | 3 | 1.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Proctozone-B | 57237-372 | Tablet, coated | Over the counter monograph drugs | October 10, 2026 |
| Senaklear | 57237-371 | Tablet, film coated | Over the counter monograph drugs | September 30, 2026 |
| Dimetane | 57237-368 | Capsule, liquid filled | Over the counter monograph drugs | January 27, 2026 |
| Dimetane | 57237-367 | Capsule, liquid filled | Over the counter monograph drugs | January 27, 2026 |
| Mucolyte DM | 57237-360 | Liquid | Over the counter monograph drugs | December 22, 2025 |
| Mucolyte | 57237-359 | Liquid | Over the counter monograph drugs | December 22, 2025 |
| Lidonumb | 57237-353 | Cream | Over the counter monograph drugs | December 18, 2025 |
| Jointiva | 57237-355 | Cream | Over the counter monograph drugs | December 16, 2025 |
| Pedikleer | 57237-354 | Cream | Over the counter monograph drugs | December 16, 2025 |
| Cetirizine hydrochloride | 57237-358 | Solution | Generic drugs (ANDA) | November 11, 2025 |
| Cetirizine hydrochloride | 57237-357 | Solution | Generic drugs (ANDA) | November 11, 2025 |
| Sodium Chloride | 57237-361 | Tablet | Over the counter monograph drugs | November 6, 2025 |
| ItchZap | 57237-352 | Cream | Over the counter monograph drugs | November 6, 2025 |
| Coolexa | 57237-351 | Cream | Over the counter monograph drugs | November 6, 2025 |
| Micoclear | 57237-350 | Cream | Over the counter monograph drugs | November 6, 2025 |
| Proctozone GMax | 57237-339 | Suppository | Over the counter monograph drugs | July 31, 2025 |
| Proctozone-G | 57237-338 | Suppository | Over the counter monograph drugs | July 31, 2025 |
| Adult Low Dose Aspirin | 57237-349 | Tablet, delayed release | Over the counter monograph drugs | July 9, 2025 |
| Acetaminophen, Aspirin and Caffeine | 57237-348 | Tablet | Over the counter monograph drugs | July 9, 2025 |
| Acetaminophen | 57237-347 | Tablet, film coated | Over the counter monograph drugs | July 9, 2025 |
| Acetaminophen | 57237-346 | Tablet, film coated | Over the counter monograph drugs | July 9, 2025 |
| Proctozone-B | 57237-337 | Suppository | Over the counter monograph drugs | December 1, 2024 |
| Meclizine HCl | 57237-333 | Tablet | Over the counter monograph drugs | July 22, 2024 |
| Diphenhydramine HCl Oral Solution | 57237-318 | Solution | Over the counter monograph drugs | December 15, 2023 |
| Diphenhydramine HCl Oral Solution | 57237-317 | Solution | Over the counter monograph drugs | December 15, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.